The metabolic landscape of RAS-driven cancers from biology to therapy

Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes metabolic dysregulation in cancer cells has advanced substantially over the last decade. In this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in cancer and elucidate the underlying mechanisms that could translate to novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers. Mukhopadhyay, Vander Heiden and McCormick review the metabolic landscape of RAS-driven cancers, the effects of RAS-directed metabolic reprogramming and opportunities for targeting these cancers therapeutically.

Automated summary

This review highlights the metabolic reprogramming mediated by oncogenic RAS in cancer and explores the potential novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers. Mukhopadhyay, Vander Heiden, and McCormick provide insights into the metabolic landscape of RAS-driven cancers, the effects of RAS-directed metabolic reprogramming, and opportunities for therapeutic targeting of these cancers.